Edition:
United States

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

155.90USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$155.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
125,996
52-wk High
$164.00
52-wk Low
$34.58

Latest Key Developments (Source: Significant Developments)

Beigene Announces Proposed Public Offering
Tuesday, 16 Jan 2018 04:04pm EST 

Jan 16 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED PUBLIC OFFERING.BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​.BEIGENE LTD - ‍BEIGENE INTENDS TO OFFER AND SELL $650 MILLION OF ITS ADSS, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES​.  Full Article

Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab
Tuesday, 9 Jan 2018 09:00am EST 

Jan 9 (Reuters) - Beigene Ltd ::BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE.BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA.  Full Article

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 06:00am EST 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​.  Full Article

Beigene presents preliminary phase 1 data for bgb-a317
Thursday, 28 Sep 2017 09:00am EDT 

Sept 28 (Reuters) - Beigene Ltd ::Beigene presents preliminary phase 1 data for bgb-a317 in chinese patients with advanced tumors at the 20th annual meeting of CSCO.Beigene Ltd - ‍adverse events assessed by investigator related to treatment occurred in 19 patients​.Beigene - ‍preliminary data suggest that bgb-a317 was generally well tolerated​.Beigene-Preliminary data suggest bgb-a317 exhibited preliminary evidence of anti-tumor activity in chinese study population with advanced solid tumors​.Beigene ltd - ‍intend to initiate phase 3 trials supporting approval in china for each of 4 tumors, lung, stomach, liver, and esophageal cancers​.Beigene ltd - ‍initial studies expected to start in q4 of 2017 or q1 of 2018 for bgb-a317 phase 3 trials​.  Full Article

Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​
Friday, 1 Sep 2017 06:18am EDT 

Sept 1 (Reuters) - Beigene Ltd :Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​.  Full Article

Beigene announces proposed public offering
Wednesday, 9 Aug 2017 04:11pm EDT 

Aug 9 (Reuters) - Beigene Ltd :Beigene announces proposed public offering.Beigene Ltd - ‍announced a public offering of adss each representing 13 of its ordinary shares, par value $0.0001 per share​.Beigene Ltd - ‍intends to offer and sell $125 million of its adss, before underwriting discounts and commissions and estimated offering expenses​.  Full Article

Celgene enters collaboration with BeiGene to advance inhibitor program for solid tumor cancers
Wednesday, 5 Jul 2017 09:00pm EDT 

July 5 (Reuters) - Celgene Corp :Celgene Corporation enters into global strategic immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers.Celgene Corp says BeiGene to receive $263 million in upfront license fees and $150 million equity investment.Celgene Corp says BeiGene to acquire Celgene's commercial operations in China and exclusive license to Celgene's China cancer commercial portfolio.Celgene Corp says BeiGene retains right to develop BGB-A317 in hematology and in combination with its other portfolio compounds.Celgene Corp says Celgene will maintain a strategic and research and development presence in China dedicated to long-term commercial activities.Celgene Corp says BeiGene is eligible to receive up to $980 million in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317.Celgene will acquire equity stake in BeiGene by purchasing 5.9 percent of BeiGene's ordinary shares at $4.58 per share.  Full Article

‍Beigene presents initial phase 1 data on BGB-A317 combined with BGB-290
Monday, 5 Jun 2017 09:00am EDT 

June 5 (Reuters) - Beigene Ltd :‍Beigene presents initial phase 1 data on anti-PD-1 antibody BGB-A317 combined with PARP inhibitor BGB-290 at 2017 American Society for Clinical Oncology Annual Meeting​.Beigene Ltd - ‍safety analysis suggested that combination of BGB-A317 and BGB-290 was generally well-tolerated in patients with advanced solid tumors​.  Full Article

Beigene files for potential mixed shelf offering
Friday, 26 May 2017 05:10pm EDT 

May 26 (Reuters) - Beigene Ltd :Beigene ltd- files for potential mixed shelf offering; size not disclosed - sec filing.  Full Article

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage: